Nanotechnology and Immunoassay

To the Editor:
The roots of nanotechnology can be traced back to colloid science in the mid-19th century. Francesco Selmi, often credited with the first true research in the field, studied the behavior of various metallic and acidic emulsions in the 1840s (1 ) . Shortly thereafter, Michael Faraday and Thomas Graham, two scientific pioneers known primarily for their work with electricity and diffusion of gases, respectively, contributed further to the analysis of nanoparticulate suspensions, i.e., colloids. Faraday's studies in electrochemistry naturally led him to the first experiments with colloidal gold (2 ) , and Graham coined the term "colloid" after noting that certain substances showed slow diffusion rates through porous membranes (3 ) .
Early applications of nanostructures in analysis included the use of colloidal gold and silver (i.e., nanosized gold and silver particles) as part of histologic stains (4 ) . Since then, the scope of analytical applications of nanotechnology has increased considerably (5 ) . One branch of analysis in which nanotechnology has had a significant impact is immunologic assays.
A broad range of nanostructures (e.g., spheres and tubes) are being used to push the detection limits and throughput of immunoassay technology. Metallic and semiconductor nanoparticles, for example, are gaining popularity as highly sensitive labels (e.g., in fluorescent detection and Raman tagging), and magnetic nanoparticles are being used as solid supports for immunoassays. In addition, the fabrication of nanobarcode structures has recently opened the door to the development of high-throughput multiplexed assays. Finally, the optimized design of self-assembled monolayer and nanoimprinted substrate surfaces has yielded precisely organized surface-immobilized antibodies, further improving the performance of immunoassays.
We 
The analysis of circulating RNA in plasma opens up new possibilities for the noninvasive monitoring of a variety of physiological and pathological conditions (1 ) . In this study, we demonstrate the usefulness of a bone marrow transplantation (BMT) model system for ascertaining the tissue origin of plasma RNA species. These data were generated as part of a project to develop plasma nucleic acid markers for brain injury. Because brain injury, such as stroke, involves cell death and disruption of the blood-brain barrier, we hypothe-sized that brain-derived nucleic acids may be released into the circulation. Hence, the measurement of brainderived RNA markers in plasma may reflect the degree of brain tissue damage.
Numerous reports indicate that S100 calcium binding protein B (S100B) is released after brain injury and its concentrations in serum are significantly correlated with injury severity and outcome (2 ) . To investigate whether S100B mRNA might be detectable in the plasma and might serve as a marker for brain injury, we used a real-time reverse transcriptase PCR assay to measure plasma S100B mRNA concentrations in 67 stroke patients and 16 healthy age-and sex-matched individuals. Among the stroke patients, stroke was diagnosed as ischemic in 48 patients and hemorrhagic in 6 patients, and 13 patients had no acute changes on computed tomography or magnetic resonance neuroimaging. Median patient scores for the National Institutes of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS) were 5 (range 0 -34) and 15 (range 4 -15), respectively. The median time from symptom onset to blood sampling was 11 h (range 1-23.8 h). Eight stroke patients died during hospitalization or within 30 days after discharge. Plasma S100B mRNA concentrations, however, showed no statistically significant differences in stroke patients compared with controls (P ϭ 0.38, Mann-Whitney test), and plasma S100B mRNA concentrations in stroke patients showed no statistically significant correlation with NIHSS or GCS scores. These unexpected results prompted us to investigate whether the detected plasma S100B mRNA was indeed derived from the brain. Previous data from a BMT model have demonstrated that hematopoietic cells are important contributors of plasma DNA. It is possible that hematopoietic cells might also contribute to the detected plasma S100B mRNA through illegitimate transcription (3 ) .
We thus proceeded to use the BMT model to test whether the hematopoietic system might indeed contribute significantly to plasma S100B mRNA. Genotypes of S100B mRNA molecules in plasma of recipients after BMT were compared with those before BMT as well as with the donor genotypes. Contribution of plasma S100B mRNA by blood cells could be inferred if the transcripts in plasma of recipients bore the donor genotypes among the informative donorrecipient pairs, in which the donor and recipient had different S100B genotypes before BMT.
The local clinical research ethics committee approved the study. Twenty-three myeloablative BMT patients who attended the Department of Paediatrics of the Prince of Wales Hospital, Hong Kong, were recruited, and informed consent was obtained from either the patients or responsible guardians. Archived pre-BMT peripheral blood mononuclear cells (PBMCs) of the recipients were retrieved for DNA extraction. A post-BMT blood sample (5 mL EDTA) was withdrawn from each patient and then centrifuged at 100g for 10 min at 4°C. Plasma and buffy coat samples were then collected separately. Plasma samples were filtered with a 5-m filter to remove any residual blood cells. Buffy coat samples were centrifuged at 230g for 5 min at 4°C, and any residual plasma was removed.
The methods of nucleic acid extraction and single nucleotide polymorphism (SNP) analysis of RNA molecules, i.e., RNA-SNP, were as previously described (4, 5 ) . In brief, the analysis was based on the detection by mass spectrometry of an SNP within an RNA transcript after a primer extension reaction. The extension products for each allele demonstrated distinct masses that could 
* Cases were considered informative because they showed distinct S100B genotypes between the donor and recipient before BMT. Post-BMT shifting of recipient's plasma S100B genotype was observed in all of these cases: A heterozygous C/T to homozygous C/C shift was observed in cases 2, 3, and 11. A heterozygous C/T to homozygous T/T shift was observed in cases 9 and 15. A homozygous T/T to heterozygous C/T shift was observed in cases 12, 14, and 16.
be resolved by MALDI-TOF mass spectrometry.
A highly polymorphic C/T SNP, rs9722 (minor allele frequency 0.43), located within the coding region of S100B was selected from the Sequenom RealSNP Assay Database. Post-BMT plasma S100B genotypes of recipients were determined from the RNA specimens that were extracted from the recipients' post-BMT plasma samples. Pre-BMT S100B genotypes of the recipients were determined from the DNA specimens that were extracted from the archived pre-BMT PBMC samples of the recipients. The S100B genotypes of the bone marrow donors were determined from both DNA and RNA specimens that were extracted from the post-BMT buffy coat samples of the corresponding recipients.
As shown in Table 1 , 8 of 23 donorrecipient pairs were informative. The S100B mRNA genotypes in the plasma of these recipients were altered after BMT and became identical to those of the corresponding donors.
Our study has clearly demonstrated that after BMT the S100B mRNA in recipient plasma switched to the donor's genotype. Thus, plasma S100B was predominantly of hematopoietic origin and could not be used as a brain-specific plasma marker. Hence, caution is required in the interpretation of the presumed tissue origin of plasma RNA markers. The BMT model described here can provide a valuable confirmation step for showing or excluding the hematopoietic contribution of a plasma RNA marker.
